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Abstract
The improvements in outcomes associate with the use of preoperative therapy rather than postoperative treatment
means that clinical teams are increasingly reliant on imaging to identify high-risk features of disease to determine
treatment plans. For many solid tumours, including rectal cancer, validated techniques have emerged in identifying
prognostic factors pre-operatively. In the MERCURY study, a standardised scanning technique and the use of
reporting proformas enabled consistently accurate assessment and documentation of the prognostic factors. This is
now an essential tool to enable our clinical colleagues to make treatment decisions. In this review, we describe the
proforma-based reporting tool that enables a systematic approach to the interpretation of the magnetic resonance
images, thereby enabling all the clinically relevant features to be adequately assessed.
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Introduction
The last few years have seen improvements in survival
of patients with a diagnosis of rectal cancer through
improvements in surgical, oncological treatment, plan-
ning and follow-up. One of the key aspects of planning
treatment is the staging information provided by radiolo-
gists to the multidisciplinary team. As with most solid
malignancies, precise staging and anatomical delineation
of the tumour enables preoperative treatment and radical
surgery to improve outcomes in high-risk patients and
equally prevent unnecessary and harmful over-treatment
of patients with good prognosis or early stage tumours.
We are now moving into an era of individualising treat-
ments according to both risk of local and distant failure
and the imaging is as crucially important as the tumour
type and genetic susceptibility. The aim of this article is
to consider proforma reporting as a tool that enables the
systematic assessment of patients with newly diagnosed
rectal cancer.
Why should we use proforma
reporting?
We have traditionally relied on freeform text reporting to
provide the radiological opinion of the tumour appear-
ance and extent. However, when these reports are audited
there is generally a lack of specific cancer staging detail
that compromises the ability to consistently obtain the
necessary staging data required for modern cancer man-
agement. In the past, free text reporting was also the
standard for colorectal pathology reporting but audits
of minimum data for staging of these freeform reports
showed significant missing data. The pathology assess-
ment of circumferential resection margin status in
rectal cancers is a crucial prognostic factor strongly pre-
dicting for local recurrence and results in postoperative
therapy. In the 1997 pathology audit, this was only
reported in a third of patients[1]. Following the introduc-
tion of minimum data set reporting in histopathology,
these rates improved to almost 100% resulting in better
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selection of patients who could benefit from postopera-
tive adjuvant therapy. The same arguments can be
applied to imaging with patients potentially benefiting
from imaging-based preoperative treatments.
As has been shown in pathology audits, the absence
of explicitly stated prognostic factors in reports can result
in false-negative assumptions and can potentially lead
to under staging and under treatment of patients[2]. In
a recent audit of proforma versus non-proforma reporting
in radiology, key staging data was missing in 97% of
freeform reports; the introduction of proforma reporting
resulted in missing data in only 3% of reports. Magnetic
resonance imaging (MRI) assessment of the potential
circumferential resection margin, which is the main
factor that determines the use of preoperative chemora-
diotherapy, was missing in 74% of non-proforma reports.
With the introduction of proforma reporting this reduced
to 4% (Mangat et al., Proceedings of RSNA 2009).
Therefore, proforma reporting encourages:
 accurate and reliable baseline documentation of
disease
 analysis of imaging-related prognostic data in the
future may help better target patients in clinical
trials receiving novel therapies and effective imple-
mentation based on such on imaging characteristics
 the ability to compare baseline pre-treatment
tumour phenotype images will provide us with
much needed data regarding the effects of treat-
ments on disease
There are other wider benefits for patients: national
audits have demonstrated unacceptable variation in sur-
gical practice and outcomes between regions and trusts
for different cancers but without the imaging baseline
and detailed and systematic documentation of the stage
of tumours it is not possible to make any meaningful
comparisons.
In 2002, we undertook a prospective European, mul-
ticentre, multidisciplinary study, with emphasis on qual-
ity control of imaging assessment, surgery, and
pathology, to assess the diagnostic accuracy, feasibility,
and reproducibility of MRI in predicting the final his-
topathological staging of tumour within 1 mm of the
circumferential resection margin (MERCURY study).
In the study, we used proformas, based on published
national guidelines, to ensure quality control in collect-
ing data. Before the launch of the study, all radiologists
attended intensive training workshops, using compara-
tive materials from MRI and histopathology. These
workshops focused on interpretation of images and
acquisition techniques, which require considerable spe-
cialist skill and were an important part of the success
in achieving consistency and reproducibility in this
multicentre trial.
In this article, we describe the rectal cancer staging
proforma and image interpretation techniques to aid its
completion.
Proforma reporting technique
in rectal cancer
A proforma recommended for use in staging rectal can-
cers is illustrated in Appendix 1.
Tumour morphology
As with pathology reporting, it is helpful to the clinical
teams to provide a general description of the morphology
of the tumour. Rectal cancers can be polypoidal with a
low signal intensity stalk that attaches the tumour to the
rectal wall or annular with varying degrees of central
ulceration. Polypoidal lesions tend to have a smaller inva-
sive front and extend beyond the rectal wall through the
stalk (Fig. 1). Annular ulcerating tumours are character-
ized by a central ulcer/crater with raised rolled edges.
They invade at the ulcer crater with either a smooth or
more nodular infiltrating border (Fig. 2). The latter is
associated with a poorer prognosis and higher rate of
metastatic failure [38]. It is very rare for rectal tumours
to show intramural spread and this would be noteworthy
for the surgeon in planning the distal resection
margin. Current recommendation allows a 1-cm distal
clearance[911]. Mucinous tumours are characterized by
evidence of high signal intensity pools within the tumour
[12] and are associated with a worse prognosis in the
rectum. This is thought to be due to the fact that they
infiltrate diffusely and unlike annular or polypoidal
tumours they may spread intramurally[10,13].
Tumour height
The height of the tumour is given from the anal verge as
this is a useful reference point for surgeons. It is
Figure 1 Polypoidal lesions tend to have a smaller
invasive front and extend beyond the rectal wall through
the stalk.
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measured from the lowest point to the raised rolled edge
of the tumour to the anal verge (Fig. 3). Traditionally the
rectum has been divided into thirds, as outcomes and
surgical management are affected by the height of the
tumour:
(1) Upper: the lowest edge of the tumour is higher than
10 cm from the anal verge. The anterior wall of
the upper rectum is covered by the peritoneal reflec-
tion; the risk of peritoneal perforation of these
tumours and the risk of trans-coelomic spread is
high for such patients, and a warning to the surgeon
will enable careful dissection and mobilisation of the
rectum in such cases to minimize the risk of tumour
spillage[14,15].
(2) Middle: lowest point between 5 cm and 10 cm. This
segment of the rectum lying below the peritoneal
reflection is completely encircled by mesorectum
and will therefore be suitable for total mesorectal
excision (TME). The surgical margins will be
formed by the mesorectal fascia which is the plane
of dissection in TME surgery[16].
(3) Lower: tumour below 5 cm from the anal verge, the
area of rectum and mesorectum below the origin of
the levators where the mesorectum tapers sharply,
makes both the surgical approach and the interpre-
tation of images challenging.
T staging and depth of tumour spread
beyond the muscularis propria
Within each T stage there is a heterogeneous survival
range and there has been much interest in identifying
poor prognostic groups within each stage. Both T1 and
T2 tumours have high 5-year survival rates but the widest
range in survival is demonstrated in patients with T3
tumours, which make up 80% of rectal tumours seen
in clinical practice. The relationship between survival
and the depth of extramural spread in millimetres is
well established and it is independent of other prognostic
factors including the circumferential margin status[17,18].
The more recent TNM classifications now take into
account the body of evidence that enables the subclassi-
fication of T3 tumours as follows (T3a 51mm; T3b
15mm; T3c4515mm; T3d415mm). Dukes original
observations noted that with increasing depth of spread,
there was an increased rate of nodal spread and distant
failure. This is reflected in better disease-free survival for
patients with T355mm (T3a, T3b) versus those with
T3c or T3d tumours at presentation.
The MERCURY study group showed that depth of
extramural tumour spread was accurate compared with
the histopathology reference standard validating MRI as
a method of accurate preoperative prognostication using
depth of extramural spread.
On T2-weighted images, the mucosal layer is demon-
strated as a fine low signal intensity line with the thicker,
higher signal submucosal layer seen beneath this.
The muscularis propria is often visualised as two dis-
tinct layers: the inner circular layer and the outer longi-
tudinal layer. The outer muscle layer has an irregular,
somewhat corrugated appearance with interruptions
due to vessels entering the rectal wall. The perirectal fat
appears as high signal surrounding the low signal of the
muscularis propria and contains signal void vessels. The
mesorectal fascia is seen as a fine low signal layer envel-
oping the perirectal fat and rectum and it is this layer that
Figure 3 The height of the tumour is given from the anal
verge as this is a useful reference point for surgeons. It is
measured from the lowest point to the raised rolled edge of
the tumour to the anal verge.
Figure 2 Annular ulcerating tumours are characterized
by a central ulcer/crater with raised rolled edges. They
invade at the ulcer crater with either a smooth or more
nodular infiltrating border. The latter is associated with a
poorer prognosis and higher rate of metastatic failure[16].
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defines the surgical excision plane in TME anterior resec-
tions[16]. MRI diagnosis of a tumour spread beyond the
muscularis propria is based on the presence of tumour
signal extending into the perirectal fat with a broad-based
bulging or nodular configuration in continuity with the
intramural portion of the tumour (Fig. 4). It is important
to note the continuity with the intramural component as
there can be disruption to the outer longitudinal layer as
a result of small vessels penetrating the wall, not neces-
sarily invaded by tumour. The depth of extramural spread
is measured in millimetres beyond the outer edge of the
longitudinal muscle coat.
Low rectal tumours
The commencement of the puborectalis sling marks the
start of the narrowest part of the mesorectum, which at
this point tapers to form a thin segment of perirectal fat.
Below the puborectalis sling lies the anal canal, which is
formed of the mucosa and submucosa, the internal
sphincter, the 1- to 2-mm intersphincteric plane and the
external sphincter. At this level there is no mesorectum,
which higher in the rectum acts as a protective barrier to
contain tumour. Therefore any spread beyond the mus-
cularis propria would result in exposure of tumour at
the margins if an ultra-low TME or conventional plane
abdominoperineal excision (APE) is undertaken (Fig. 5).
This is because for the conventional plane of surgery, the
muscularis propria rather than the mesorectal fascia
forms the surgical margins. Therefore this plane can
only be considered safe if a good thickness of preserved
muscularis propria is visible deep to the invasive border
of the tumour. If the muscularis propria is fully replaced
by tumour or has minimal extension into the
intersphincteric plane, then a more radical surgical
approach is required in the form of an extralevator/extra-
sphincteric APE that removes the entire sphincter com-
plex, levators and mesorectum en bloc.
Extramural venous invasion
Pathological studies of vascular invasion in the early
1980s[1921] first established the body of evidence of
the prognostic significance of vascular invasion.
Amongst these histological studies, the rate of detection
of vascular invasion was variable with reported inci-
dences ranging from 17% to 70%[19,2228]. Whereas
lymph node status becomes less predictive of local failure
in patients undergoing careful radical excision of
the rectum and mesorectum, venous invasion remains
an important independent prognostic factor[29,30].
Therefore extramural venous invasion (EMVI) is con-
sidered to be an important risk factor for both local
recurrence[27], distant metastases[25,3134] and
death[25,27,3540].
MRI is the only imaging modality that has been shown
to consistently demonstrate EMVI in rectal cancer[41]
and is depicted as discrete serpiginous or tubular projec-
tions of intermediate signal intensity into perirectal fat,
following the course of a visible perirectal vein (Fig. 6).
We have devised an MRI-EMVI grading score to evaluate
the presence or absence of radiological features indicative
of EMVI[42], and in a recent study carried out in our own
unit we found that the proportion of patients with MRI-
detected EMVI rectal and rectosigmoid cancers undergo-
ing primary surgery was 26%, which was similar to the
histologically proven proportion (28%). The sensitivity
and specificity of MRI for detecting EMVI in this
Figure 4 MRI diagnosis of a tumour spread beyond the
muscularis propria is based upon the presence of tumour
signal extending into the perirectal fat with a broad-based
bulging or nodular configuration in continuity with the
intramural portion of the tumour.
Figure 5 At this level there is no mesorectum, which,
higher in the rectum, acts as a protective barrier to contain
tumour. Therefore any spread beyond the muscularis
propria would result in exposure of tumour at the margins
if an ultra-low TME or conventional plane APE is
undertaken.
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series was 62% and 88%, respectively. The relapse-free
survival at 3 years was 35% for patients with an MRI-
EMVI score of 34, compared with 74% for those with a
score of 02 (P50.001); this was similar to values in
patients with positive and negative histological EMVI
status, respectively (34 vs 73.7%; P50.001). Therefore
MRI assessment of EMVI is an important pro-
gnostic factor that can be readily detected and predicts
outcome[43].
Nodal stage
Nodal staging has traditionally relied on size of the nodes
on MRI criteria, however several studies have indicated
the inaccuracy of using this technique alone. Criteria
based on the outline of the node and features of signal
intensity have been shown to be more reliable[44,45] It
may be in the future that this will be augmented by
using contrast agents as early results have been quite
promising[46].
Lymph nodes should only be evaluated on high-resolu-
tion (minimum in-plane resolution 0.6 0.6 mm, slice
thickness 3mm). Nodes can then be classified according
to their appearance. Uniform, homogenous signal inten-
sity nodes are not considered to be suspicious. Nodes are
judged suspicious if they have irregular borders or mixed
signal intensity or both (Fig. 7)[44]. The prognostic
importance of lymph nodes in patients undergoing
TME is uncertain and most patients with 3 or fewer
involved nodes have a good prognosis. However, patients
with a heavier nodal burden (4 or more involved nodes)
are known to have a worse prognosis but are also more
likely to present with other more easily identifiable poor
prognostic features on MRI, namely extramural venous
invasion and increasing depth of extramural spread.
Distance to circumferential
resection margin
The mesorectal fascia represents the potential circumfer-
ential resection margin (CRM) in patients undergoing
TME surgery. Bissett et al.[47,48] conclusively demon-
strated by using markers that the mesorectal fascial
plane seen with MRI corresponds to the fascia propria
encasing the mesorectum and excised by TME. MRI can
therefore be used to assess the distance from the tumour
edge to the potential circumferential margin and thereby
predict the final CRM status in patients undergoing TME
surgery.
Studies have used different cut-off values of the mea-
sured distance to the mesorectal fascia to predict CRM
status. The authors of one study concluded that CRM
status could be predicted with a high degree of accuracy
and consistency[49] when a cut-off of 5mm MRI mea-
sured distance to the CRM was used. Other authors
have been able to use more precise MRI measurements
to predict CRM status. Our own prospective study invol-
ving 98 patients undergoing preoperative MRI staging
predicted the CRM status to be positive when tumour
was identified by MRI within 1 mm of the meso-
rectal fascia. Comparison with histology showed very
good (92%, k¼ 0.81) agreement[41] and in the
MERCURY study, the 1-mm cut-off correctly predicted
the CRM status[50].
Figure 7 Lymph nodes should only be evaluated on high
resolution (minimum in plane resolution 0.6\0.6 mm,
slice thickness 3 mm). Nodes can then be classified accord-
ing to their appearance. Uniform, homogenous signal
intensity nodes are not considered to be suspicious.
Nodes are judged suspicious if they have irregular borders
or mixed signal intensity or both[8].
Figure 6 MRI is the only imaging modality that has been
shown to consistently demonstrate extramural vascular
invasion in rectal cancer[7] and is depicted as discrete
serpiginous or tubular projections of intermediate signal
intensity into perirectal fat, following the course of a vis-
ible perirectal vein.
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Measurements are taken for the distance of tumour to
the mesorectal fascia, the potential CRM of the tumour.
A potentially positive margin is defined as tumour lying
within 1mm of the mesorectal fascia (Fig. 8). This is
taken for:
(a) the main tumour
(b) suspicious lymph nodes
(c) extramural vascular invasion
(d) tumour deposit/satellite (a tumour deposit53mm
is classed as a nodule and 43mm classed as a
node)
Pelvic sidewall lymph nodes
We record the location of the node, size, site and if there
are any suspicious features according to the morpholog-
ical criteria stated above (Fig. 9). This may be a further
predictor of survival and local recurrence[51].
Post chemoradiotherapy assessment
of tumour regression
For those patients who received preoperative chemora-
diotherapy we used a tumour regression grade analysis,
grade 15, modified from Dworak et al.[52]. This is
known to be a better predictor for outcome after treat-
ment compared with T stage (Fig. 10)[53].
The universal adoption of proforma reporting will
enable us to provide standardised comparisons to help
in future national audits and improve treatment policies
in cancer centres. A joint working group of the Royal
College of Radiologists and the National Cancer
Intelligence Network has been set up to develop web-
based tools to support radiologists in their multidisciplin-
ary team preparations so that they can effectively provide
key data that is so crucial to the management of patients
with cancer.
Figure 10 Post chemoradiotherapy assessment of tumour
regression. For those patients who received preoperative
chemoradiotherapy we used a tumour regression grade
analysis, grade 15, modified from Dworak et al.[9] This
is known to be a better predictor for outcome after treat-
ment compared with T stage.
Figure 8 Measurements are taken for the distance of
tumour to the mesorectal fascia, the potential CRM of
the tumour. A potentially positive margin is defined as
tumour lying within 1 mm of the mesorectal fascia.
Figure 9 We record the location of the node, size, site
and if there are any suspicious features according to the
morphological criteria stated above.
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Appendix 1
Patient Name: _________________________________ Patient No:_______________ Date of Birth:_______ 
MRI Pelvis (Rectal Cancer) 
Primary tumour:   annular     ulcerating            villous      polypoidal 
  eroding     mucinous            signet      not easily shown 
Height from anal verge: _________  mm 
Distal edge lies:   at puborectalis sling     ____mm            above puborectalis sling 
Extends craniocaudally over: _________  mm 
Lies (peritoneal reflection): _________  mm       above (PR)               below (PR) 
Invading edge of tumour: from  _________  o’clock          to _________  o’clock 
Muscularis propria:   confined to     extends through 
Extramural spread: _________  mm 
T stage:        T1        T2        T3a        T3b        T3c        T3d       T4a      T4b        N/A 
Free Text Additional comments: 
For low rectal tumours at or below the puborectalis sling 
Submucosal layer/part thickness of muscularis propria : intersphincteric plane/mesorectal plane is safe 
intersphincteric APE or ultra low TME possible. 
Full thickness of muscularis propria : intersphincteric plane/mesorectal plane is unsafe, Extralevator APE. 
Into intersphincteric plane : intersphincteric plane/mesorectal plane is unsafe, for extralevator APE. 
Into External sphincter : intersphincteric plane/mesorectal plane is unsafe. 
Beyond External sphincter into ischiorectal tissue : intersphincteric plane / mesorectal plane is unsafe. 
Malignant lymph nodes: 
 At level of tumour:   None      Present number _____ mixed signal/irregular border 
 Above level of tumour:   None      Present number _____ mixed signal/irregular border 
Extramural venous invasion:   No evidence     Evidence 
  Small     Medium          Large 
Closest circumferential resection margin: _________  o’clock 
Minimum tumour distance to mesorectal fascia: _________  mm,    CRM clear    CRM involved 
Closest CRM lies at distance from anal verge: _________  mm 
Peritoneal involvement:   No evidence     Evidence  
Pelvic side wall lymph nodes:   None     Benign            Malignant 
Summary:        Overall stage:       T _______               N ________  
  CRM clear         CRM involved    EMVI positive   EMVI negative  
  M0                     M1                       Good prognosis   Poor prognosis  
By imaging criteria, eligible for:                                            Discussion points for imaging case: 
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Patient Name: _________________________________ Patient No:_______________ Date of Birth:_______ 
Post Treatment Assessment 
Complete as above plus Tumour regression grade assessment of Tumour response:           
  Tumour signal only, no fibrosis,TRG5   
  >50% tumour, <25% fibrosis, TRG4          
  50% tumour/fibrosis, TRG 3 
  >75% fibrosis, TRG2   
  No tumour TRG1 
Overall stage: y MRI T ________ N  ________  
  CRM clear      CRM involved (fibrosis)                           CRM involved (tumour)   
  EMVI positive     EMVI negative  
  M0     M1   good prognosis   poor prognosis  
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